Sohonos (Palovarotene) Sets Milestone as First Drug for Ultra-Rare Bone Disease
XTalks
AUGUST 21, 2023
“For the first time, doctors have an approved medicine available to them, shown to reduce the formation of new, abnormal bone growth, known as heterotopic ossification (HO), which causes debilitating mobility challenges and has a devastating impact on the lives of people with FOP.”
Let's personalize your content